The double-blind, placebo-controlled study targets adults aged 30 and older diagnosed with either the Parkinsonian or cerebellar subtype of MSA. Researchers are tracking safety through the incidence of adverse events, while secondary endpoints utilize the Unified Multiple System Atrophy Rating Scale and 10-meter walk tests to measure clinical progress. YA-101 functions as a D-amino acid oxidase inhibitor, designed to suppress neuroinflammation and boost plasticity in the brain.

Dr. Jane Tseng, CEO of the Taipei-based firm, noted that the data will serve as the foundation for upcoming global licensing discussions. The drug has already secured Fast Track status from the U.S. FDA and Orphan Drug Designations across the U.S., Japan, and the European Union. Currently, Multiple System Atrophy remains a fatal neurodegenerative condition with no approved disease-modifying treatments, leaving patients to rely solely on symptomatic relief. Dasher Neuroscience is simultaneously preparing for a Phase 3 trial as it seeks to address a market that impacts tens of thousands of individuals across the globe.